4-硝基苯乙烷磺酰氯 | 80259-15-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-硝基苯乙烷磺酰氯
• 中文别名: 2-(4-硝基-苯基)-乙磺酰氯；2-(4-硝基苯基)乙烷磺酰氯
• 英文名称: 2-(4-nitro-phenyl)ethanesulfonyl chloride
• 英文别名: (p-nitrophenyl)ethylsulfonyl chloride；NpesCl；2-(4-nitro-phenyl)-ethanesulfonyl chloride；2-(4-Nitro-phenyl)-aethansulfonylchlorid；2-(4-nitrophenyl)-ethane sulfonyl chloride；2-(4-nitrophenyl)ethanesulfonyl Chloride
• CAS: 80259-15-0
• 化学式: C₈H₈ClNO₄S
• mdl: MFCD06657958
• 分子量: 249.675
• InChiKey: LCUFMYFBIXFCMV-UHFFFAOYSA-N

物化性质

• 熔点：
  81.5-83℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-硝基苯乙烷磺酰氯 在 20percent Pd(OH)2/C 盐酸 、 氨 、 氢气 、 sodium cyanoborohydride 、 potassium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 甲醇 、 溶剂黄146 、 乙腈 为溶剂， 20.0 ℃ 、310.27 kPa 条件下， 反应 7.0h， 生成 N-[2-[4-[[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]amino]phenyl]ethylsulfonyl]benzamide
  参考文献：
  名称：

  Synthesis and Evaluation of Potent and Selective β₃ Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres

  摘要：

  Starting from phenethanolamine aniline leads 3a and 3b, we have identified a series of functionally potent and selective beta(3) adrenergic receptor (AR) agonists containing acylsulfonamide, sulfonylsulfonamide, or sulfonylurea groups within the aniline phenethanolamine series. In beta(3) beta(2), and beta(1) AR cAMP functional assays, 3a and other right-hand side (RHS) carboxylate analogues were found to be full agonists that were modestly selective against beta(1) or beta(2) ARs, while analogues lacking RHS acid functionality were active at beta(3) AR but not selective. Replacement of the carboxylate with acylthiazole and acylmethylsulfone gave potent, but only modestly selective, compounds. Increasing the size of the RHS sulfonamide substituent with phenyl or p-toluene afforded compounds with good potency and functional selectivity (beta(3) AR pEC(50) greater than 8; beta(1) and beta(2) AR selectivity greater than 40- and 500-fold, respectively). Our SAR studies suggest that the potency and selectivity profile of the best analogues reported here is a result of both the steric bulk and acidity of the RHS sulfonamide NH group. Although all of the analogues had a pharmacokinetic half-life of less than 2 h, acylsulfonamides 43 and 44 did show moderately low clearance in dogs. These two compounds were further evaluated by thermographic imaging in mice and were found to produce a robust thermogenic response via oral administration.

  DOI：

  10.1021/jm0101500
• 作为产物：
  描述：

  1-氯-2-(4-硝基苯基)乙烷 在 甲基安非他命 、 氯 、 sodium thiosulfate 、 溶剂黄146 作用下， 生成 4-硝基苯乙烷磺酰氯
  参考文献：
  名称：

  核苷。零件LIX。2-（4-硝基苯基）乙基磺酰基（Npes）基团：核苷化学中的新型保护类型† •

  摘要：

  2-（4-硝基苯基）乙基磺酰基（npes）基团被开发为核糖核苷系列中新的糖OH封闭基团。可以在非质子条件下以β-消除过程进行裂解，使用1,8-二氮杂双环[5.4.0]十一碳-7-烯（DBU）作为最有效的碱基。由于磺酸盐不显示酰基迁移，因此可能会部分保护1,2-顺式-二醇部分，从而导致新型的寡核苷酸构建基团。一系列由Markiewicz保护的核糖核苷1-10转化为它们的2'- O- [2-（4-硝基苯基）乙基磺酰基]衍生物29-38，其中5'-OSi键可通过酸水解裂解形成39- 45。随后的单甲氧基三苯甲基化导致46-50，和脱甲硅基，得到5'- ø - （单甲氧）-2'- ö - [2-（4-硝基苯基）乙基磺酰基]核糖核苷51-55。酸处理去除三苯甲基也不会伤害npes组（56-58）。完全封闭的2'- O- [2-（4-硝基苯基）乙基磺酰基]核糖核苷96-102的明确合成是通过相应的3'-

  DOI：

  10.1002/hlca.19950780706

文献信息

• Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents
  作者：William A. Denny、Bruce F. Cain、Graham J. Atwell、Corwin Hansch、Augustine Panthananickal、A. Leo

  DOI：10.1021/jm00345a015

  日期：1982.3

  relationships (QSAR) have been derived between antileukemic (L1210) activity and agent physicochemical properties for 509 tumor-active members of the general class of 9-anilinoacridines. One member of this class is the clinical agent m-AMSA (NSC 249992). Agent hydrophobicity proved a significant but not a dominant influence on in vivo potency. The electronic properties of substituent groups proved important

  已针对9类苯胺基between啶类化合物中的509种肿瘤活性成员，在抗白血病（L1210）活性与药物理化性质之间建立了定量关系（QSAR）。此类药物之一是临床药物m-AMSA（NSC 249992）。试剂疏水性已证明对体内效力有显着但非主要的影响。取代基的电子性质被证明是重要的，但是对药物效力的最显着影响是通过位于9-苯胺基cr啶骨架上不同位置的基团的空间影响显示出来的。这些结果与这些化合物发挥作用的重要生理步骤完全一致，它们是通过在碱基对之间插入idine啶发色团并在小沟中放置苯胺基而将它们与双链DNA结合的，如前所述。还推导了9-苯胺基cr啶的643种衍生物的急性毒性方程。该方程采用与模拟抗白血病药效价相似的形式，强调了抗肿瘤药的药效和急性毒性之间通常相当紧密的关系。这项研究证明了QSAR技术的强大功能，可以构建大量的生物学数据，并允许从中提取有用的信息，这取决于有关化合物的可能作用部
• 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
  申请人：Player R. Mark

  公开号：US20080114007A1

  公开（公告）日：2008-05-15

  The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R 101 and R 200 are described in the specification.

  本发明针对当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求，提供对c-fms激酶的强效抑制剂。本发明涉及以下式I的新化合物： 或其盐、对映体、互变异构体、结晶、多晶型、无定形、溶剂化物、水合物、酯、前药或代谢物形式，其中A、Y、Z、R 101 和R 200 在说明书中有描述。
• [EN] PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE DARUNAVIR ET D'INTERMÉDIAIRES DE DARUNAVIR
  申请人：MAPI PHARMA HK LTD

  公开号：WO2011092687A1

  公开（公告）日：2011-08-04

  The present invention relates to a process for the preparation of darunavir, a nonpeptide protease inhibitor (PI), useful for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens. The present invention further relates to processes for the stereo-directed preparation of darunavir intermediates, in particular (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-ol and to certain novel intermediates obtained by such processes.

  本发明涉及一种用于制备达芦那韦的方法，达芦那韦是一种非肽类蛋白酶抑制剂（PI），用于治疗患有多药耐药HIV-1变异株的HIV/AIDS患者，这些变异株对先前存在的HAART方案没有反应。本发明还涉及用于立体定向制备达芦那韦中间体的方法，特别是(3R,3aS,6aR)-六氢呋喃[2,3-b]呋喃-3-醇，以及通过这些方法获得的某些新型中间体。
• 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
  申请人：Player R. Mark

  公开号：US20070060577A1

  公开（公告）日：2007-03-15

  The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R 101 and R 200 are described in the specification.

  该发明通过提供c-fms激酶的有效抑制剂来解决当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求。该发明涉及公式I的新化合物：或其溶剂化合物、水合物、互变异构体或药用可接受的盐，其中：W、A、Y、Z、R101和R200如规范中所述。
• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20070249649A1

  公开（公告）日：2007-10-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  该发明涉及以下式I的化合物：其中Z、X、J、R2和W如规范中所述，以及其溶剂合物、水合物、互变异构体和药用可接受的盐，这些化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。提供了治疗自身免疫疾病的方法；以及具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、Paget病和其他骨吸收导致发病率的疾病，包括关节炎、假体失败、破骨性肉瘤、骨髓瘤和肿瘤转移至骨骼的方法，使用式I的化合物也提供了。